Go Here Test

More Diets

Go Here Test

Neratinib

Pronounced

"ne-RA-ti-nib"

Common brand names:

Nerlynx

Uses

Neratinib is used to treat breast cancer. Neratinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

How to Use This Medication

Read the Patient Information Leaflet if available from your pharmacist before you start taking neratinib and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

Take this medication by mouth with food as directed by your doctor, usually once daily. Swallow the medication whole. Do not crush, chew, or split the tablets. Avoid handling or touching crushed or broken tablets.

Use this medication regularly to get the most benefit from it. To help you remember, take it at the same time each day.

The dosage is based on your medical condition and response to treatment. To reduce your risk of side effects, your doctor may direct you to start this medication at a low dose and gradually increase your dose. Follow your doctor's instructions carefully. Do not increase your dose or use this drug more often or for longer than prescribed. Your condition will not improve any faster, and your risk of serious side effects will increase.

To help prevent diarrhea, your doctor should prescribe anti-diarrhea medication (such as loperamide) for you to take on a regular schedule during the first 2 months of treatment with neratinib. Follow your doctor's directions to keep taking anti-diarrhea medication on a regular schedule or to take it only as needed.

Medications which reduce or block stomach acid (such as proton pump inhibitors-PPIs, H2 blockers, antacids) may reduce the absorption of neratinib, making it work less well. Do not take PPIs (such as omeprazole, lansoprazole) while using this medication. If you take an antacid, take it at least 3 hours before taking neratinib. If you take a H2 blocker (such as famotidine, ranitidine), take it at least 10 hours before or at least 2 hours after taking neratinib.

Avoid eating grapefruit or drinking grapefruit juice while using this medication unless your doctor or pharmacist says you may do so safely. Grapefruit can increase the chance of side effects with this medicine. Ask your doctor or pharmacist for more details.

Since this drug can be absorbed through the skin and lungs and may harm an unborn baby, women who are pregnant or who may become pregnant should not handle this medication or breathe the dust from the tablets.

Copyright © 2025 TraceGains, Inc. All rights reserved.

RxAnswers™ is a copyrighted combined product from TraceGains and First DataBank, Inc.

Drug information is selected from data included with permission and copyrighted by First DataBank, Inc. This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional. Always seek the advice of your healthcare professional if you have any questions about this product or your medical condition. This information is not intended as individual medical advice and does not substitute for the knowledge and judgment of your healthcare professional. This information does not contain any assurances that this product is safe, effective or appropriate for you.

This information is intended only for residents of the United States. Products sold under the same brand names in other countries may contain different ingredients.

Learn more about First DataBank

There are some limitations on the information provided in “Nutrient Interactions.” Do NOT rely solely on the information in this article. Please read the disclaimer.

Learn more about TraceGains, the company.

TraceGains and/or its suppliers make no warranties or representations as to the accuracy or completeness of this content herein or that of any organization referred or linked to within this content and will not be liable for any damages arising out of your access to or use of any information found herein or that of any organization referred to within this content.

Information expires December 2025.